Report an error

Spotted something inaccurate in “BTK Inhibitor Zanubrutinib Shows Superior Outcomes in High-Risk CLL Patients”? Tell us what’s wrong and we’ll check it against the original source.

Website

Send report Cancel

This form is for factual corrections. We read every report but cannot reply individually.